Research ArticleCancer

Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies

See allHide authors and affiliations

Science Translational Medicine  03 Jul 2019:
Vol. 11, Issue 499, eaau9240
DOI: 10.1126/scitranslmed.aau9240

Article Information

vol. 11 no. 499

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 27, 2018
  • Accepted for publication May 20, 2019
  • .

Author Information

  1. Roheena Z. Panni1,
  2. John M. Herndon2,
  3. Chong Zuo2,
  4. Samarth Hegde2,
  5. Graham D. Hogg2,
  6. Brett L. Knolhoff2,
  7. Marcus A. Breden2,
  8. Xiaobo Li3,
  9. Varintra E. Krisnawan2,
  10. Samia Q. Khan3,
  11. Julie K. Schwarz4,5,
  12. Buck E. Rogers4,5,
  13. Ryan C. Fields1,4,
  14. William G. Hawkins1,4,
  15. Vineet Gupta3,* and
  16. David G. DeNardo2,4,6,*,
  1. 1Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
  2. 2Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  3. 3Drug Discovery Center, Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA.
  4. 4Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
  5. 5Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  6. 6Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  1. Corresponding author: ddenardo{at}wustl.edu
  • * These authors contributed equally to this work as senior authors.

Altmetric

Article usage

Article usage: July 2019 to September 2019

AbstractFullPdf
Jul 2019927535312107
Aug 20195217559293
Sep 2019316157126